Medasense appoints Dr. Dagan Harris as VP Clinical and Regulatory Affairs to lead the clinical strategy and oversee International regulatory pathways for the Company’s pain monitoring device, PMD200™. 

Dr. Harris brings vast experience in clinical trial management, having previously served in various clinical leadership positions in companies such as Orsan, NanoVibronix, Ultrashape and Mindguard.  Prior to joining Medasense, he was the VP Clinical Affairs at Orsan, a brain monitoring device developer, where he managed large scale clinical trials and oversaw their U.S and International regulatory pathways. His role with NanoVibronix means he also brings direct experience working within the pain sector. Dr. Harris holds a Ph.D. in Biochemistry and an MBA specializing in Health Administration from the Tel Aviv University, Israel.

“As a skilled clinical and regulatory professional with a wealth of experience working in both the pain sector and in monitoring device companies, Dagan brings a unique skill-set to lead our clinical and regulatory activities,” said Galit Zuckerman, CEO of Medasense. 

To learn more about Medasense, please visit our website